• David Lillicrap.
• Richardson Laboratory, Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada. lillicrap@cliff.path.queensu.ca
• Pediatr Blood Cancer. 2013 Jan 1;60 Suppl 1:S44-7.

AbstractWe are in the midst of an unprecedented period for the development of new therapeutic products to treat patients with bleeding diseases. While current hemostatic treatments are already very effective and safe, new agents to enhance convenience and further improve both short- and long-term efficacy of treatment are under development. Some of these products have already reached the clinic for early phase trials, and others will be available shortly. The strategies being evaluated for hemostatic enhancement range from gene and nucleic acid-based approaches, to the development of complex, naturally occurring molecules such as the non-anticoagulant polysaccharide, fucoidan. There is every likelihood that combinations of these treatment approaches will further improve the quality of bleeding disease management over the next 5 years and beyond.Copyright © 2012 Wiley Periodicals, Inc.

14 keywords...

hide…